Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Peiwen Yang

Matched on ORCID iD 0000-0003-2929-1334; OpenAlex author ID A5028145641. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 3 papers

Papers 11

  1. Role of PTK6 in the diagnosis, prognosis, and immune infiltration of pancreatic cancer based on evidence from bioinformatics analysis and experimental validati… Co-author DOI 10.1007/s12672-026-05115-9↗
  2. Luteolin Triggers Pyroptosis in Pancreatic Ductal Adenocarcinoma by Inhibiting Mitochondrial Fission through the RAS/ERK/DRP1 Pathway. Co-author DOI 10.1142/s0192415x26500606↗
  3. Bufalin Suppresses Pancreatic Ductal Adenocarcinoma Through ER Stress-Ferroptosis Crosstalk Associated with IP3R-Linked Ca2+ Dysregulation and ATF3/SLC7A11 Reg… Co-author DOI 10.3390/ijms27104373↗
  4. Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.phymed.2025.157048↗
  5. Modified Sijunzi Decoction Inhibits Pancreatic Cancer Progression and Improves Immune Suppression: Network Pharmacology and Experimental Validation. Co-author DOI 10.2147/dddt.s520390↗
  6. Novel silicene-mesoporous silica nanoparticles conjugated gemcitabine induced cellular apoptosis via upregulating NF-κB p65 nuclear translocation suppresses pa… Co-author DOI 10.1088/1361-6528/ad312a↗
  7. "Huanglianjiedu Decoction" Against Pancreatic Adenocarcinoma Proliferation of by Downregulating the PI3K/AKT/mTOR and MAPK/ERK1/2 Signaling Pathways. Co-author DOI 10.1177/2515690x241291381↗
  8. Cynanchum paniculatum (Bunge) Kitag. ex H.Hara inhibits pancreatic cancer progression by inducing caspase-dependent apoptosis and suppressing TGF-β-mediated ep… Co-author DOI 10.3389/fphar.2024.1284371↗
  9. Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation. Co-author DOI 10.1186/s10020-023-00648-z↗
  10. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer. Co-author DOI 10.1016/j.jep.2022.115516↗
  11. Fibroblast activation protein-based theranostics in pancreatic cancer. First author DOI 10.3389/fonc.2022.969731↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chien‐shan Cheng · 6 shared papers, 2022–2024 · strength 1.35
  2. Waimei Si · 4 shared papers, 2025–2026 · strength 1.18
  3. Xin Li · 4 shared papers, 2025–2026 · strength 1.18
  4. Linjie Ruan · 4 shared papers, 2023–2026 · strength 1.09
  5. Zhen Chen · 4 shared papers, 2022–2026 · strength 1.01
  6. Juying Jiao · 4 shared papers, 2022–2026 · strength 1.00
  7. Yuan Zhang · 3 shared papers, 2025–2026 · strength 0.87
  8. He Ba · 3 shared papers, 2025–2026 · strength 0.87
  9. Shu Dong Ma · 3 shared papers, 2022–2024 · strength 0.70
  10. Lianyu Chen · 2 shared papers, 2024 · strength 0.54
  11. Xiaoyan Zhu · 2 shared papers, 2022–2026 · strength 0.48
  12. Panling Xu · 2 shared papers, 2022–2024 · strength 0.42
  13. Shu-Lin Yu · 1 shared paper, 2026 · strength 0.36
  14. Yue Fan · 1 shared paper, 2026 · strength 0.36
  15. Fang Wang · 1 shared paper, 2026 · strength 0.36
  16. Zhen Chen · 1 shared paper, 2026 · strength 0.32
  17. Lixia Yi · 1 shared paper, 2026 · strength 0.30
  18. Zhen Chen · 1 shared paper, 2025 · strength 0.28
  19. Yuhang Chen · 1 shared paper, 2024 · strength 0.28
  20. Jingxian Chen · 1 shared paper, 2024 · strength 0.23
  21. Lan Zheng · 1 shared paper, 2024 · strength 0.23
  22. Jiabin Jin · 1 shared paper, 2024 · strength 0.23
  23. Fengjiao Wang · 1 shared paper, 2023 · strength 0.22
  24. Shaoli Song · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.